NCT06876662

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 279 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Conditions

• Chronic Lymphocytic Leukemia
• Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	Pirtobrutinib	Administered orally.

Timeline

• Start date: 2025-05-20
• Primary completion: 2030-05-01
• Completion: 2032-12-01
• First posted: 2025-03-14
• Last updated: 2026-03-02

Locations

36 sites across 8 countries: United States, Australia, France, Italy, Japan, Poland, South Korea, United Kingdom

Regulatory

• FDA-regulated drug study